Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy

Eye (Basingstoke)

Volumn 12, Issue 3, 1998, Pages 343-349

  Lee, Vickie ^a   Bentley, Christopher R ^a   Olver, Jane M ^a  

^a WESTERN EYE HOSPITAL   (United Kingdom)

Author keywords

5 Fluorouracil; Canaliculitis; Epiphora; Sclerosing

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DACRYOCYSTOGRAPHY; DNA SYNTHESIS; EARLY DIAGNOSIS; EPIPHORA; EYE TOXICITY; FEMALE; FIBROSIS; HUMAN; LACRIMAL DUCT OCCLUSION; LACRIMATION; SILASTIC TUBE;

EID: 0031854791     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.1998.83     Document Type: Article

References (23)

1. Jacobs EM, Luce JK, Wood DA. Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer 1968;22:1233-8.
2. Caravella LP, Burns JA, Zangmeister M. Punctal-canalicular stenosis related to systemic fluorouracil therapy. Arch Ophthalmol 1981;99:284-6.
3. Seiff SR, Shorr N, Adams T. Surgical treatment of punctalcanalicular fibrosis from 5-fluorouracil therapy. Cancer 1985;56:2148-9.
4. Brink HMA, Beex LVA. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Doc Ophthalmol 1995;90:1-6.
5. Greenspan E. Combination cytotoxic chemotherapy in advanced disseminated breast cancer. J Mt Sinai Hosp 1972;33:1-27.
6. Kende G, Sirki SR, Thomas PRM, et al. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer 1979;44:69-71.
7. Jack MK, Hicks JD. Ocular complications in high dose chemoradiotherapy and marrow transplantation. Ann Ophthalmol 1981;13:709-11.
8. Fraunfelder FT, Meyers SM. Ocular toxicity of antineoplastic agents. Ophthalmology 1983;90:1-3.
9. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer therapy. Surv Ophthalmol 1989;34:220-30.
10. Bonadonna G, Brusamolino E, Pinuccia V, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
11. Doroshow JH, Locker GY, Gasterland DE, et al. Ocular irritation from high dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer 1981;48:2158-62.
12. Stern WH, Guerin CJ, Erickson P A, Lewis GP, Anderson DB, Fisher SK. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol 1983;96:43-51.
13. Shapiro MS, Thoft RA, Friend J, Parrish RK, Gressel MG. 5- Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci 1985;26:580-3.
14. Straus DJ, Mausolf FA, Ellerby RA, McCracken JD. Cicatricial ectropion secondary to 5-fluorouracil therapy. Med Pediatr OncoI 1977;3:15-9.
15. Hammersley J, Luce JK, Florent TR, Burkholder MM. Excessive lacrimation from fluorouracil treatment. JAMA 1973;225:747-8.
16. Christophidis N, Vajda FJE, Lucas I, Drummer 0, Moon WJ, Louis WJ. Excessive lacrimation associated with detectable concentrations of 5FU in tears and plasma. Proc Aust Soc Clin Exp Pharmacol 1977;23:56.
17. Aisner J, Weinberg V, Perloff R, Weiss M, Korzun A, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFP v CMF Each ± MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 1987;5:1523-33.
18. Jones LT. Epiphora. II. Its relation to the anatomical structures and surgery of the medial canthal region. Am J Ophthalmol 1957;43:203-12.
19. Becker BB. Tricompartmental model of the lacrimal pump mechanism. Ophthalmology 1992;99:1139-45.
20. Hurwitz JJ. Canalicular diseases. In: Hurtwitz JJ, editor. The lacrimal system. New York: Lippincott-Raven, 1996:139-47.
21. Veirs ER, Brindley GO. Management of canalicular obstruction. Adv Ophthalmic Plast Reconstruct Surg 1984;3:165-9.
22. Barishak R, Romano A, Stein R. Obstruction of lacrimal sac caused by topical epinephrine. Ophthalmologica 1969;159:373-9.
23. Silkiss R, Axelrod RN, Iwach AG, Vassiliadis A, Hennings DR. Transcanalicular THC:YAG dacryocystorhinostomy. Ophthalmic Surg 1992;23:351-3.